Major approved MS therapies by ARR United States 2014

This statistic displays the major currently approved therapies for multiple sclerosis (MS) as of 2014 in the United States, by annualized relapse rate (ARR). During this year, EMD Serono's Rebif, approved in 2002, had an ARR of 32 percent. There are about 350,000 to 500,000 people in the country that are diagnosed with the disease. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.

Selected approved multiple sclerosis therapies as of 2014, ranked by ARR*

Product (company, year of approval, route)	Annualized relapse rate relative risk reduction over 2 years
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

July 2014

More information

Region

United States

Survey time period

2014

Supplementary notes

* ARR = annualized relapse rate.
** For mitoxantrone, the primary outcome measure for efficacy in the progressive types of MS was a composite of five elements: Expanded Disability Status Scale (EDSS) scores, Ambulation Index, number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status. Data in the table for mitoxantrone have been extracted from the study; however, these were not the primary outcome measures.
***ARR for Tecfidera ranges from 44 to 53.

Citation formats